Low-Dose Triple-Pill Combination Reduces Recurrent Stroke Risk by 40% in Global Trial

The TRIDENT randomized controlled trial, led by The George Institute for Global Health and published in The New England Journal of Medicine, found that GMRx2 reduced recurrent stroke risk by approximately 40% in patients with intracerebral hemorrhage and high blood pressure. GMRx2 is a single pill combining three low-dose blood pressure medications, offering a simplified treatment approach for this high-risk patient population. The trial results demonstrate significant risk reduction for stroke survivors managing hypertension after intracerebral hemorrhage.

TRIDENT Trial Results and Stroke Risk Reduction

• ▪GMRx2 reduced recurrent stroke risk by 40% according to the TRIDENT trial results.
• ▪The TRIDENT randomized controlled trial was led by The George Institute for Global Health.
• ▪Treatment with GMRx2 significantly reduced the risk of another stroke in patients with intracerebral hemorrhage and high blood pressure in the TRIDENT trial.
• ▪Results from the TRIDENT randomized controlled trial are published in The New England Journal of Medicine.

GMRx2 Triple-Pill Combination Treatment Approach

• ▪GMRx2 was tested in patients with intracerebral hemorrhage and high blood pressure.
• ▪GMRx2 is a single pill combination of three low-dose blood pressure medicines.

Perspective of The George Institute for Global Health

• ▪GMRx2 represents a potential breakthrough in managing blood pressure for intracerebral hemorrhage survivors.
• ▪The TRIDENT trial demonstrates that a simplified triple-pill approach can effectively prevent recurrent strokes in high-risk patients.

Perspective of Stroke survivors with intracerebral hemorrhage and hypertension

• ▪A single daily pill combining three medications may be easier for stroke survivors to adhere to than multiple separate prescriptions.
• ▪Patients with intracerebral hemorrhage and high blood pressure face substantial risk of experiencing another stroke.

1 source